The London Biotechnology Show 2026 will return to ExCeL London on 18–19 November, bringing together biotechnology and pharmaceutical companies, researchers, healthcare professionals, investors, policymakers and technology providers
Philips' Oxygenate 5 launch puts home oxygen therapy access, affordability and long-term respiratory care in India under the spotlight as COPD-related healthcare needs grow nationally.
Health Ministry launches Tobacco Free Youth Campaign 4.0, targeting colleges and universities to close tobacco free gaps across Indian states.
Apollo Hospitals has launched an AI-assisted stroke care programme, raising questions about how AI stroke triage can accelerate emergency decisions and improve treatment pathways.
Fortis Suguna Hospital acquisition adds 110 beds in Bengaluru, with planned clinical upgrades and expansion offering potential for long-term growth.
TB Alliance loses patent fight in India as rejection of its six-month BPaL cure patent supports affordable drug-resistant tuberculosis treatment.
Lilly’s triple agonist retatrutide outmuscles Ozempic on weight loss, delivering greater weight reduction and blood sugar control in trials.
Cancer drugs are facing new price controls in India, but unchanged prices for several patented therapies raise questions about affordability and patients' actual treatment expenses.
GSK share price falls despite a third quarter earnings beat as weaker vaccine sales, Shingrix and Arexvy disappoint investors.
Artiva's AlloNK discontinuation raises questions about autoimmune cell therapy safety, fludarabine toxicity, and whether early clinical responses can deliver lasting benefits in autoimmune disease treatment.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
